Retatrutide

  • Retatrutide is a multi-agonist peptide that stimulates three receptors: GLP-1, GIP, and glucagon. By activating these receptors, it promotes weight loss, improves glycemic control, and enhances metabolic function. The GLP-1 and GIP agonist effects reduce appetite and increase insulin sensitivity, while the glucagon receptor activity promotes energy expenditure and lipid metabolism.

  • • Significant weight reduction through appetite suppression and increased energy expenditure

    • Improved glycemic control by reducing fasting and postprandial blood glucose levels

    • Enhanced insulin sensitivity

    • Reduction in liver fat content in NAFLD/NASH

    • Improvement in lipid profiles (reduced LDL cholesterol and triglycerides)

    • Cardiovascular risk reduction through weight loss and improved metabolic markers

    • Maintenance or increase of lean body mass during weight loss

    • Reduction in inflammatory markers associated with obesity

    • Enhanced metabolic rate due to glucagon receptor activation

    •Long-term adherence potential due to weekly dosing

  • • Obesity management

    • Type 2 diabetes mellitus

    • Pre-diabetes or impaired glucose tolerance

    • Non-alcoholic fatty liver disease (NAFLD)

    • Non-alcoholic steatohepatitis (NASH)

    • Cardiovascular risk reduction in obese individuals

    • Insulin resistance

    • Hyperlipidemia

    • PCOS with metabolic syndrome

    •Weight loss in preparation for bariatric surgery

    • Jastreboff, A. M., et al. (2023). “Retatrutide in the management of obesity: A phase 2 trial.” The New England Journal of Medicine, 389(11), 1003-1012.

    • Wilding, J. P., et al. (2022). “Clinical efficacy of GLP-1 receptor agonists in combination with GIP and glucagon receptor agonism.” Diabetes, Obesity and Metabolism, 24(3), 523-533.

    • Frias, J. P., et al. (2023). “Safety and efficacy of multi-agonist peptides in treating type 2 diabetes and obesity.” Nature Medicine, 29(2), 174-184.

    • Rosenstock, J., et al. (2023). “Retatrutide as a triple-agonist therapy for metabolic disorders.” The Lancet Diabetes & Endocrinology, 11(5), 321-330.

    • Drucker, D. J., et al. (2023). “Advancements in GLP-1, GIP, and glucagon receptor therapies for metabolic health.” Cell Metabolism, 35(4), 677-689.

    • Astrup, A., et al. (2022). “Multi-agonist peptides and weight loss: A new era in obesity treatment.” Obesity Reviews, 24(1), e13568.

    • Chiu, M., et al. (2022). “The role of retatrutide in treating NASH and NAFLD.” Hepatology Research, 52(3), 345-352.

    • Holst, J. J., et al. (2023). “Physiological mechanisms behind GLP-1 and glucagon receptor activation for obesity.” Annual Review of Physiology, 85(1), 421-443.

    • Nauck, M. A., et al. (2023). “Combining incretin and glucagon therapies: Retatrutide’s potential.” Journal of Endocrinology and Metabolism, 68(4), 197-205.

    • Vilsbøll, T., et al. (2022). “Understanding the long-term effects of retatrutide on metabolic health.” Endocrine Reviews, 44(2), 245-256.